CompletedPhase 1NCT00537147

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults

Studying West-Nile encephalitis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Anna Durbin, M.D.
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
Intervention: WN/DEN4delta30 vaccine(biological)
Enrollment: 26 enrolled
Eligibility: 18-50 years · All sexes
Timeline: 2008 – 2009

Study locations (2)

Center for Immunization Research, Johns Hopkins School of Public Health (DC Location), Washington D.C., District of Columbia, United States
Center for Immunization Research, Johns Hopkins School of Public Health (MD Location), Baltimore, Maryland, United States

Collaborators

Johns Hopkins Bloomberg School of Public Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00537147 on ClinicalTrials.gov

Other trials for West-Nile encephalitis

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07094724
High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients
Gili Regev-Yochay MD

See all trials for West-Nile encephalitis →

← Back to all trials